

Fisher&Paykel HEALTHCARE






FY04 Highlights

- Operating revenue up 28% to US\$132M, 3% to NZ\$215M
- Operating profit up 33% to US\$49M,
 7% to NZ\$79M
- Operating margin of 36.8%
- Pre-tax return on average shareholders' equity of 42%
- R&D investment increased to 6.6% of revenue






Sales by Product Group





Sales by Region

FY04








Expanding Global Presence







Respiratory Humidification







Respiratory Humidification

- Revenue growth US\$
 FY04 +34%, underlying
 growth approx 14%
- SARS ≈ US\$2M
- Sales growth driven by chamber and circuit sales, MR850 share gains
- Continued market share growth in breathing circuits







Respiratory Humidification

Revolutionary dry tube technology introduced

 Non-invasive ventilation circuit, weaning kit, catheter mount introduced

 Filters growing strongly adding value per patient

 New humidifier systems in R&D pipeline







Dry Tube Technology







New Market Opportunities

- COPD project
- Humidification system for laparoscopic insufflation



MR860 Humidifier system for laparoscopic insufflation





Obstructive Sleep Apnea







Obstructive Sleep Apnea

Flow generator and mask revenue growth US\$ FY04 +35%, 2H04 +45%

 Total revenue growth US\$ FY04 +17%

HC221LE flow generator introduced

 HC211 convertible flow generator introduced, expands market opportunity





New masks



HC407 FlexiFit™ Nasal Mask



HC431 FlexiFit™ Full Face Mask





Neonatal

- Revenue growth US\$ FY04 +63%
- Strong infant warmer revenue growth, favourable customer mix
- Growing acceptance of Neopuff infant resuscitator and neonatal CPAP system
- Increasing consumable revenue



IW930 Cosycot Infant Warmer





Neonatal





RD900 Neopuff Infant Resuscitator Neonatal Breathing System





Patient Warming

Introduced second generation patient warmer with proprietary single use sensor.







Fisher&Paykel HEALTHCARE

